Interventions and therapeutic compounds of trials included for review
| Intervention | No of articles/abstracts | Therapeutic compound | Target |
| csDMARDs, csDMARD combination vs other csDMARDs or placebo | 3 | MTX+SSZ + HCQ vs MTX+LEF + HCQ | Dihydrofolate reductase+purine metabolism; dihydroorotate dehydrogenase |
| MTX (+5 mg every 4 wks) vs MTX (+5 mg every 2 wks) | |||
| MTX+SSZ + GC vs MTX+GC vs MTX+LEF + GC vs MTX | |||
| bDMARD±csDMARDs vs placebo | 8 | Opineracept | TNF receptor |
| Denosumab | RANKL | ||
| Rituximab | CD20 | ||
| Olokizumab | IL-6 | ||
| Sarilumab | IL-6 receptor | ||
| Levilimab | |||
| tsDMARDs±csDMARDs vs placebo | 7 | Baricitinib | JAK1,2 |
| Filgotinib | JAK1 | ||
| Upadacitinib | JAK1,2 | ||
| bDMARDs vs other bDMARDs | 4 | Rituximab vs Tocilizumab | CD20 vs IL6 receptor |
| Olokizumab vs Adalimumab | IL6 receptor vs TNF | ||
| Certolizumab pegol+MTX vs Abatacept+MTX vs. Tocilizumab+MTX | TNF vs CD80/CD86 vs IL6R | ||
| tsDMARDs vs bDMARDs | 3 | Upadacitinib vs Adalimumab | JAK1,2 vs TNF |
| Upadacitinib vs Abatacept | JAK1,2 vs CD-80/CD-86 | ||
| Filgotinib vs Adalimumab | JAK1 vs TNF | ||
| Biosimilars | 2 | bsDMARDs of infliximab, etanercept, adalimumab | TNF/TNFR |
| Strategic studies | 4 | ||
| Switching between tsDMARDs and bDMARDs | 1 | Upadacitinib <-> Adalimumab | JAK1,2 <-> TNF |
| csDMARD dose reduction and stopping | 3 | csDMARDs | |
| bDMARD dose reduction and stopping | 7 | Adalimumab | TNF |
| Etanercept | TNFR | ||
| Infliximab | TNF | ||
| Tocilizumab | IL6R | ||
| Rituximab | CD20 | ||
| Any TNFi | TNF | ||
| csDMARD or bDMARD dose reduction or stopping | 5 | Etanercept/MTX | TNFR |
| Abatacept/MTX | CD80/CD86 | ||
| Any csDMARD/any bDMARD | |||
| Any csDMARD/any TNFi |
b, biologic; CD, cluster of differentiation; cs, conventional synthetic; DMARD, disease-modifying antirheumatic drug; HCQ, hydroxychloroquine; IL, interleukin; JAK, Janus Kinase; LEF, leflunomide; MTX, methotrexate; RANKL, receptor activator of nuclear factor kappa-Β ligand; SSZ, sulfasalazine; TNF, tumour necrosis factor alpha; TNFi, TNF alpha inhibitor; ts, targeted synthetic; wk, week.